[1] |
Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper[J]. Ann Oncol, 2016,27(4):559⁃574. doi: 10.1093/annonc/mdv623.
|
[2] |
李明, 周博洋, 李邻峰. PD⁃1/PD⁃L1抑制剂的皮肤不良反应[J]. 中国麻风皮肤病杂志, 2019,35(8):509⁃512.
|
[3] |
Carlos G, Anforth R, Chou S, et al. A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab[J]. Melanoma Res, 2015,25(3):265⁃268. doi: 10.1097/CMR.0000000000000155.
|
[4] |
Lopez AT, Khanna T, Antonov N, et al. A review of bullous pemphigoid associated with PD⁃1 and PD⁃L1 inhibitors[J]. Int J Dermatol, 2018,57(6):664⁃669. doi: 10.1111/ijd.13984.
|
[5] |
Damsky W, Kole L, Tomayko MM. Development of bullous pemphigoid during nivolumab therapy[J]. JAAD Case Rep, 2016,2(6):442⁃444. doi: 10.1016/j.jdcr.2016.05.009.
|
[6] |
Papay J, Krenacs T, Moldvay J, et al. Immunophenotypic profiling of nonsmall cell lung cancer progression using the tissue microarray approach[J]. Appl Immunohistochem Mol Morphol, 2007,15(1):19⁃30. doi: 10.1097/01.pai.0000213143. 32030.f5.
|
[7] |
Krenacs T, Kiszner G, Stelkovics E, et al. Collagen XVII is expressed in malignant but not in benign melanocytic tumors and it can mediate antibody induced melanoma apoptosis[J]. Histochem Cell Biol, 2012,138(4):653⁃667. doi: 10.1007/s00418⁃ 012⁃0981⁃9.
|
[8] |
Altman EM. Novel therapies for pemphigus vulgaris. Am J Clin Dermatol, 2020,21(6):765⁃782. doi: 10.1007/s40257⁃020⁃00 544⁃w.
|
[9] |
Stingeni L, Bianchi L, Minotti V, et al. Erlotinib⁃induced bullous pemphigoid[J]. J Am Acad Dermatol, 2012,67(5):e199⁃201. doi: 10.1016/j.jaad.2012.01.034.
|
[10] |
Jour G, Glitza IC, Ellis RM, et al. Autoimmune dermatologic toxicities from immune checkpoint blockade with anti⁃PD⁃1 antibody therapy: a report on bullous skin eruptions[J]. J Cutan Pathol, 2016,43(8):688⁃696. doi: 10.1111/cup.12717.
|
[11] |
Grän F, Goebeler M, Gesierich A. Bullous pemphigoid developing upon immune checkpoint inhibition with nivolumab[J]. Eur J Dermatol, 2019,29(4):448⁃449. doi: 10.1684/ejd.2019. 3614.
|
[12] |
Aggarwal P. Disproportionality analysis of bullous pemphigoid adverse events with PD⁃1 inhibitors in the FDA adverse event reporting system[J]. Expert Opin Drug Saf, 2019,18(7):623⁃633. doi: 10.1080/14740338.2019.1619693.
|
[13] |
Weber JS, Hodi FS, Wolchok JD, et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma[J]. J Clin Oncol, 2017,35(7):785⁃792. doi: 10.1200/JCO.2015.66.1389.
|
[14] |
Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune⁃related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline[J]. J Clin Oncol, 2018,36(17):1714⁃1768. doi: 10.1200/JCO.2017.77.6385.
|
[15] |
Siegel J, Totonchy M, Damsky W, et al. Bullous disorders associated with anti⁃PD⁃1 and anti⁃PD⁃L1 therapy: a retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy[J]. J Am Acad Dermatol, 2018,79(6):1081⁃1088. doi: 10.1016/j.jaad.2018. 07.008.
|